Stoke Therapeutics-2026-JPM.pdf

《Stoke Therapeutics-2026-JPM.pdf》由会员分享，可在线阅读，更多相关《Stoke Therapeutics-2026-JPM.pdf（19页珍藏版）》请在三个皮匠报告上搜索。

1、 COPYRIGHT 2026|STOKE THERAPEUTICS|COPYRIGHT 2026|STOKE THERAPEUTICS|1Stoke Therapeutics NASDAQ:STOKIan F.SmithChief Executive Officer and Director44th Annual J.P.Morgan Healthcare Conference January 13,2026 COPYRIGHT 2026|STOKE THERAPEUTICS|Forward-Looking Statements and Other Legal Notices2This pr

2、esentation has been prepared by Stoke Therapeutics,Inc.(“Stoke”or“us”)for informational purposes only and not for any other purpose.Nothing contained in this presentation is,or should be construed as,a recommendation,promise or representation by the presenter(s)or Stoke or any officer,director,emplo

3、yee,agent or advisor of Stoke.This presentation does not purport to be all-inclusive or contain all of the information you may desire.Information provided in this presentation speaks only as of the date hereof.Stoke assumes no obligation to publicly update any information or forward-looking statemen

4、t,whether written or oral,that may be made from time to time,whether as a result of new information,future developments,subsequent events,or circumstances after the date hereof,or to reflect the occurrence of unanticipated events.This presentation contains forward-looking statements within the meani

5、ng of the“safe harbor”provisions of the Private Securities Litigation Reform Act of 1995,including,but not limited to:the ability of zorevunersen to treat the underlying causes of Draven syndrome and reduce seizures or show improvements in behavior or cognition at the indicated dosing levels or at a

6、ll;the design,timing and results of clinical studies,data readouts,regulatory decisions and other presentations for zorevunersen and STK-002;the potential for zorevunersen to be a first-in-class,disease-modifying therapy for Draven syndrome;our confidence in the demand for and the timing of enrollme